Literature DB >> 30506121

L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza's syndrome.

Upinder Kaur1, Pritam Das2, Indrajeet Singh Gambhir2, Sankha Shubhra Chakrabarti3.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30506121     DOI: 10.1007/s10072-018-3662-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  12 in total

Review 1.  Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes.

Authors:  R J Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

2.  A lethal convergence of dopamine and calcium.

Authors:  D James Surmeier
Journal:  Neuron       Date:  2009-04-30       Impact factor: 17.173

3.  Amlodipine-induced myoclonus.

Authors:  Eric L Wallace; Kevin Lingle; Dwayne Pierce; Scott Satko
Journal:  Am J Med       Date:  2009-04       Impact factor: 4.965

4.  Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza's syndrome.

Authors:  Hélio A G Teive; Renato Puppi Munhoz; Henrique B Ferraz
Journal:  Arq Neuropsiquiatr       Date:  2009-09       Impact factor: 1.420

Review 5.  Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

Authors:  Tara Swart; Michael J Hurley
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

6.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

Review 7.  Drug-induced movement disorders.

Authors:  Dénes Zádori; Gábor Veres; Levente Szalárdy; Péter Klivényi; László Vécsei
Journal:  Expert Opin Drug Saf       Date:  2015-06       Impact factor: 4.250

Review 8.  The clinical approach to movement disorders.

Authors:  Wilson F Abdo; Bart P C van de Warrenburg; David J Burn; Niall P Quinn; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

Review 9.  Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.

Authors:  Hélio A G Teive; André R Troiano; Francisco M B Germiniani; Lineu C Werneck
Journal:  Parkinsonism Relat Disord       Date:  2004-06       Impact factor: 4.891

10.  Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2013-10-30       Impact factor: 3.575

View more
  2 in total

1.  Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-03       Impact factor: 3.307

Review 2.  Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.

Authors:  Delia Tulbă; Mioara Avasilichioaiei; Natalia Dima; Laura Crăciun; Paul Bălănescu; Adrian Buzea; Cristian Băicuș; Bogdan Ovidiu Popescu
Journal:  Biomedicines       Date:  2022-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.